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Background: Aim of the present study was to evaluate prognostic factors, in particular standard laboratory
parameters, for better outcome after idiopathic sudden sensorineural hearing loss (SSNHL).
Methods: Using a retrospective review, 173 patients were included presenting between 2006 and 2009 with
unilateral SSNHL, ≥30 dB bone conduction in three succeeding frequencies between 0.125 to 8 kHz in pure tone
audiometry (PTA), and a time interval between first symptoms and diagnostics≤ 4 weeks. Hearing gain of <10 dB
versus ≥10 dB in the affected ear in 6PTA values was the primary outcome criterion. Univariate and multivariate
statistical tests were used to analyze predictors for better outcome.
Results: The initial hearing loss was 50.6 ± 27.2 dB. The absolute hearing gain was 15.6 ± 20.1 dB. Eighty-one patients
(47%) had a final hearing gain of ≥10 dB. Low-frequency hearing loss (p <0.0001); start of inpatient treatment <4 days
after onset (p = 0.018); first SSNHL (versus recurrent SSNHL, p = 0.001); initial hearing loss≥ 60 dB (p < 0.0001); an initial
quick value lower than the reference values (p = 0.040); and a pretherapeutic hyperfibrinogenemia (p = 0.007) were
significantly correlated to better outcome (≥10 dB absolute hearing gain). Multivariate analysis revealed that
first SSNHL (p = 0.004), start of treatment <4 days after onset (p = 0.015), initial hearing loss≥ 60 dB (p = 0.001),
and hyperfibrinogenemia (p = 0.032) were independent prognostic factors for better hearing recovery.
Conclusion: Better hearing gain in patients with hyperfibrinogenemia might be explained by the rheological
properties of the applied therapy and supports the hypothesis that SSNHL is caused in part by vascular factors.
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Idiopathic sudden sensorineural hearing loss [SSNHL) is
defined as unexplained unilateral sensorineural hearing
loss of 30 dB HL or greater over 3 continuous frequen-
cies with onset over a period of less than 72 hours and
with no marked vestibular symptoms [1]. SSNHL has an
estimated incidence between 160 and 400 per 100,000
persons per year, i.e. much higher than assumed in older
studies [2,3]. The causes of SSNHL are speculative
and probably multifactorial [4]. Cardiovascular disease,
cigarette smoking, and hypertension appear to be the
most common risk factors associated with SSNHL [2,4].* Correspondence: orlando.guntinas@med.uni-jena.de
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unless otherwise stated.Advanced age, severe hearing loss, heredity, audiogram
shape, and presence of vertigo seem to be significant
negative prognostic factors [4,5]. Most studies analyzing
prognostic factors do not evaluate if the therapy itself
applied to the patients with SSNHL has an influence on
these prognostic factors. Furthermore, most studies in-
clude a variety of therapy regimes and sometimes also
patients who did not receive any therapy. This makes it
difficult to interpret the concrete role of the discovered
risk factors. In a recent study using a uniform standard-
ized therapy consisting of carbogen inhalation and oral
prednisone, the prognostic factors for better recovery
were severity of initial hearing loss, presence of vertigo,
time between onset and treatment, the hearing of the
other ear, and the audiogram shape [5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cussed to be related to the etiology of SSNHL, it is sur-
prising that so far the prognostic impact of the entire
range of routine laboratory values has not been evalu-
ated systematically. Therefore, the present study investi-
gated whether patients with SSNHL and its comorbidity
also influence routine pretherapeutic laboratory values
and whether these values have prognostic influence on
hearing recovery after a standardized combined gluco-
corticoid and rheological therapeutic regime.
Methods
Patients
A standardized retrospective analysis was performed in
the Department of Otorhinolaryngology of the University
Hospital Jena in Germany. The study protocol was ap-
proved by the institutional ethics committee of the
Friedrich-Schiller University, Jena, Germany. All adult
patients who were treated for unilateral idiopathic sud-
den sensorineural hearing loss between 2006 and 2009
were included in the database for this study. Prerequis-
ite was a differential diagnostic evaluation excluding a
specific etiology (like head trauma, vestibular schwan-
noma) explaining the sudden hearing loss. All patients
received a brainstem electrical response audiometry
(BERA). If the BERA was pathologic, a magnetic reson-
ance imaging (MRI) of the head and cerebellopontine
angle was performed. Further inclusion criterion was
that at least 2 pure-tone audiograms were available: the
first at presentation prior to initiation of therapy, and a
second after therapy. If more than one follow-up
audiogram was available, the last audiogram was taken
for analysis. Follow-up audiometry was stopped when
no further hearing improvement was seen. Exclusion
criteria were: Hearing loss <30 dB bone conduction in
three succeeding frequencies between 0.125 to 8 kHz
as revealed by pure tone audiometry; time interval
between first symptoms and diagnostics > 4 weeks;
acute bilateral hearing loss; combination with acute
vestibular hypofunction (excluded by caloric vestibular
testing); history of chronic ear disease (like otoscler-
osis, chronic otitis media, Menière’s disease). A search
of the patients’ electronic charts was performed, and
the following variables were obtained: age, sex, smoking be-
havior (yes/no), Charlson comorbidity index [6], presenta-
tion of a metabolic syndrome (if patient had ≥3 of the
following diseases: diabetes mellitus, hypertension, adipos-
ity, atherosclerosis, gout, hyperlipidemia), presentation of
cardiovascular risk factors (if patients had at least 1 of the
following diseases/history of diseases: vein thrombosis, apo-
plexy, cardiac infarction, diabetes mellitus, hypertension,
hyperlipidemia) and tinnitus (yes/no).
All patients were hospitalized. Treatment followed the
German guideline for sudden idiopathic sensorineuralhearing loss as 1-week combination of glucocorticoid
and rheological therapy with pentoxifyllin [6,7]. Mainly,
a tapered course of oral corticosteroids is regarded as
standard treatment [1].
Audiometric assessment
Audiometric evaluation included air conduction and
bone conduction thresholds on the affected and the
contralateral side revealed by pure tone audiometry. The
pure tone average (PTA) was calculated from the results
of bone conduction at 0.25, 0.5, 1, 2, 4, and 6 kHz
(6PTA). The severity of the hearing loss was described
exactly according to Cvorovic et al. [5] as 1) mild, PTA
of 15 to 39 dB; 2) moderate, PTA of 40 to 59 dB; 3) se-
vere, PTA of 60 to 79 dB; 4) profound, PTA of 80 to
100 dB; and 5) deaf, PTA of greater than 100 dB [5].
Furthermore, the pattern of the initial audiogram was
categorized into 1 of 4 types [5]: Low frequencies were
defined as 0.5 kHz or less, midfrequencies as greater
than 0.5 and 2 kHz or greater, and high frequencies as
greater than 2 and 8 kHz or less. The following types of
audiograms were defined: 1) low frequency, ascending,
greater than 15 dB HL from the poorer low-frequency
thresholds to the higher frequencies; 2) midfrequency,
U-shaped, greater than 15 dB HL difference between the
poorest thresholds in the midfrequencies and those at
higher and lower frequencies; 3) high frequency, de-
scending, greater than 15 dB HL difference between the
mean of 0.5 and 1 kHz and the mean of 4 and 8 kHz; 4)
flat, less than 15 dB HL difference between the mean of
0.25-, 0.5-kHz thresholds, the mean of 1 and 2 kHz, and
the mean of 4 and 8 kHz; and 5) total deafness, hearing
loss of 100 dB or more in 0.5, 1, 2, and 4 kHz.
Hearing gain was expressed as absolute hearing gain
(Δ6PTA; dB values) from initial PTA minus dB values
from final PTA. If a negative value was calculated, the
hearing gain was set to zero. For calculation of the rela-
tive hearing gain, the absolute gain ΔPTA was divided
by the initial PTA. In order to calculate the relative hear-
ing gain in relation to the contralateral ear, ΔPTA was
divided by the initial PTA minus PTA on the contralat-
eral side [8].
Laboratory values
The assessment of pretreatment laboratory values included:
Hematologic profile with red blood cells, hemoglobin,
mean corpuscular volume (MCV), mean corpuscular
hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC), white blood cells, and plate-
lets; glucose; electrolytes covered sodium, potassium,
calcium, urea and creatinine values; the inflammation
parameter C-reactive protein (CRP); lipid metabolism
with cholesterol, low density lipoprotein (LDL), high
density lipoprotein (HDL), LDL/HDL index, and finally
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tial thromboplastin time (aPTT), and fibrinogen. The
blood samples were taken before start of treatment to
rule out an influence of the treatment on the labora-
tory values. The normal reference values for all labora-
tory parameters are given in Table 1. Most parameters
are pathological if lower or higher than the reference
range, but some are only pathological if lower than
normal range (e.g. Quick value) or higher than the nor-
mal range (e.g. CRP).
Statistical analysis
If not indicated otherwise, data are presented with mean
values ± standard deviation (SD). All statistical analyses
were performed using IBM SPSS, version 20.0. Primary out-
come criterion was absolute hearing gain (Δ6PTA) dichoto-
mized into two groups of patients (<10 dB versus ≥10 dB).Table 1 Blood values at time of diagnosis (n = 173)
Parameter Mean (SD) Median Min.
aPTT (sec) 30.3 (5.8) 29 20
Quick (%) 95.4 (24.7) 100.5 9
Fibrinogen (g/l) 3.1 (1) 3 1.3
Red-cell count (Tptl/l) women 4.6 (0.3) 4.6 3.5
Red-cell count (Tptl/l) men 4.9 (0.5) 4.9 3.7
Hemoglobin (mmol/l) women 8.5 (0.6) 8.5 7
Hemoglobin (mmol/l) men 9.1 (0.8) 9.2 6.1
Hematocrit women 0.41 (0.03) 0.4 0.34
Hematocrit men 0.43 (0.03) 0.43 0.32
White-cell count (/μl) 8462.4 (3102.6) 7600 1100
Platelet count (Gpt/l) 250 (65.7) 245 89
MCH 1.86 (0.1) 1.9 1.2
MCHC 21.1 (0.6) 21.1 18.7
MCV 88.2 (4.8) 88 63
Glucose (mmol/l) 6.7 (2.3) 5.9 3.6
Sodium (mmol/l) 140.8 (2.7) 141 130
Potassium (mmol/l) 3.9 (0.4) 3.9 2.6
Calcium (mmol/l) 2.4 (0.1) 2.4 2
Urea (mmol/l) 6.1 (2.1) 5.8 2.2
Creatinine (lmol/l) women 80 (17.4) 78 50
Creatinine (lmol/l) men 96.3 (21.3) 92 57
C-reactive protein (mg/l) 4.7 (15.3) 1.9 1.9
Cholesterol (mmol/l) 5.6 (1.1) 5.6 3.1
LDL (mmol/l) 3.3 (1) 3.3 1.2
HDL (mmol/l) 1.4 (0.4) 1.3 0.8
LDL/HDL 2.5 (0.9) 2.4 0.6
Triglycerides (mmol/l) 1.81 (1.1) 1.4 0.4
SD = standard deviation; Min = Minimum; Max =Maximum; PPT = partial thrombopla
corpuscular volume, MCH =mean corpuscular hemoglobin, MCHC =mean corpuscu
HDL = high-density lipoprotein.The chi-square test was used to compare subgroups for or-
dinal parameters (e.g. gender, side, laboratory parameters
dichotomized into normal versus pathologic values. The
non-parametric Mann-Whitney U-test was used to com-
pare subgroups for continuous parameters (e.g. age). Prog-
nostic factors associated with higher frequency of hearing
gain ≥10 dB with a probability value of p < 0.05 were in-
cluded in a binary (<10 dB versus ≥10 dB hearing gain) lo-
gistic regression analysis. Nominal p values of two-tailed
tests are reported. The significance level was set at p < 0.05.
Results
Patients’ and disease characteristics
One hundred and seventy-three (173) patients were in-
cluded into the study and constituted the database for
this study. Patients’ characteristics and details on SSNHL
are given in Table 2. The median age was 64 years. TheMax. Normal range Patients outside normal range (%)
56 26-36 39 (23)
128 70-130 17 (10)
8.7 1.8-3.5 43 (25)
5.5 4.1-5.1 9 (5)
7.2 4.5-5.9 19 (11)
10 7.6-9.5 8 (5)
10.7 8.7-10.9 21 (12)
0.48 0.35-0.45 5 (3)
0.49 0.36-0.48 4 (2)
20900 4400-11300 28 (16)
610 150-360 9 (5)
2.12 1.74-2.05 21 (21)
22.5 19.7-22.1 7 (4)
99 80-96 8 (5)
17.4 3.9-5.8 91 (53)
149 135-145 10 (6)
5.3 3.3-4.5 23 (13)
2.9 2.2-2.6 10 (6)
17.4 2.6-7.5 32 (19)
189 58-96 6 (4)
182 72-127 14 (8)
188.2 ≦ 7.5 12 (7)
9.3 ≦ 5.2 65 (38)
6.1 ≦ 4.1 22 (13)
2.8 ≧ 1.0 8 (5)
5.3 ≦ 4.1 4 (2)
7 ≦ 1.7 39 (23)
stin time Tpt/l = 103 cells per liter; Gpt/l = 109 cells per liter; MCV =mean
lar hemoglobin concentration; LDL = low-density lipoprotein;
Table 2 Patients’ characteristics (n = 173)







First SSNHL 124 (72)






Total deafness 34 (20)
Contralateral ear
Normal hearing 97 (56)











Index = 0 121 (70)
Index = 1 27 (16)
Index = 2 19 (11)







Final absolute hearing gain (Δ6PTA)
0 dB 24 (14)
1-19 dB 110 (64)
≥20 dB 39 (23)
Median, range
Age (years) 64, 18-88
Interval onset to therapy (days) 3.5, 0-28
Table 2 Patients’ characteristics (n = 173) (Continued)
Hearing loss, initial (6PTA; dB) 42.5, 14.2-110
Hearing loss, final (6 PTA; dB) 30, 0.8-105.8
Hearing gain, absolute (Δ6PTA; dB) 9, 0-100
Hearing loss, contralateral ear, initial (6PTA) 17.5, 0-120
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patients, respectively). There was no side predominance
(53% left and 47% right ear, respectively). Four of five
patients complained also of tinnitus in the affected ear.
Only 14% of patients were smokers. About two of three
patients (70%) had no relevant comorbidity according to
Charlson comorbidity index but half of the patients
showed cardiovascular risk factors.
Due to the 6PTA, the initial hearing loss was 50.6 ±
27.2 dB. The contralateral ear had a 6PTA of 21.2 ±
15.7 dB. The contralateral ear had a 6PTA of <20 dB, i.e.
a normal hearing result, in 56% of the cases. Three pa-
tients were deaf on the contralateral ear. The interval
between onset of hearing loss and begin of in-patient
therapy was 5.7 ± 6.1 days. The average follow-up period,
i.e. the time from first to last audiogram without further
hearing improvement, was 51.0 ± 44.9 days (range: 10 –
280 days).
Overall recovery
The absolute hearing gain between the initial audiogram
and the final audiogram was 15.6 ± 20.1 dB. The mean
relative hearing gain was 27.6 ± 23.7%. The mean relative
hearing gain in relation to the contralateral side was
49.4 ± 45.6%. Eighty-one patients (47%) had a final
hearing gain of ≥10 dB. Twenty-nine patients (17%)
had a relative hearing gain of ≥50%. Seventy-two pa-
tients (42%) had a relative hearing gain in relation to
the contralateral side of ≥50%.
Prognostic impact of clinical and laboratory parameter
An overview about the serology results at time of diagnosis
is presented in Table 1. Blood parameters were very variable
in the study sample. About half of the patients had elevated
glucose values. About one third had elevated cholesterol
and a about quarter elevated triglyceride values. One quar-
ter showed a hyperfibrinogenemia.
The univariate analysis on prognostic factors for better
outcome is summarized in Table 3. The following clin-
ical parameters were significantly correlated to better
outcome (≥10 dB absolute hearing gain): Low-frequency
hearing loss had a better outcome than other audiogram
patterns (p <0.0001). Start of inpatient treatment <4 days
after onset was better than a delayed treatment ≥4 days
after onset (p = 0.018). First SSNHL had a better out-
come than recurrent SSNHL (p = 0.001), and initial hear-
ing loss ≥ 60 dB had a better outcome than an initial
Table 3 Prognostic influence of clinical and serologic
parameters on hearing gain (Δ6PTA) ≥10 dB absolute
hearing gain







Comorbidity (Charlson Index ≥1) 0.435
Vascular risk factor 0.402
Low-frequency hearing loss <0.0001
Start of inpatient treatment <4 days after onset 0.018
Interval between first and last audiogram 0.065
First SSNHL 0.001
Contralateral ear with normal hearing 0.159
Initial hearing loss≥ 60 dB <0.0001
aPTT, normal 0.905
Quick, lower than normal 0.040
Fibrinogen (g/l), high (hyperfibrinogenemia) 0.007
Red-cell count (Tptl/l) women 0.611
Red-cell count (Tptl/l) men 0.593
Hemoglobin (mmol/l) women 0.901
Hemoglobin (mmol/l) men 0.946
Hematocrit women 0.727
Hematocrit men 0.086
White-cell count (/μl) 0.433









Creatinine (lmol/l) women 0.116
Creatinine (lmol/l) men 0.497






p values in bold are p values below 0.05, i.e. significant p values.
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influence on the outcome: a quick value lower than the
reference values (p = 0.040); and a hyperfibrinogenemia
(p = 0.007).
Multivariate analysis revealed that first SSNHL (p= 0.004),
start of inpatient treatment <4 days after onset (p = 0.015),
initial hearing loss ≥ 60 dB (p = 0.001), and hyperfibrinogen-
emia (p = 0.032) were independent prognostic factors for
better hearing gain (Table 4).
Discussion
We analyzed 173 patients with unilateral SSNHL treated
within four years with a standardized treatment proto-
col. Interested in predictors of the prognosis, we focused
not only on clinical and audiological data like in several
previous studies, but included also all laboratory values
of clinical routine into the univariate and multivariate
analysis. Interestingly, two serologic markers with influ-
ence on the rheology of the blood, a lower quick value
(<70%) and a hyperfibrinogenemia (fibrinogen > 3 g/l),
were associated with better outcome.
In comparison to other studies, the observed median
initial hearing loss was high with 42.5 dB. Absolute me-
dian hearing gain after combined prednisolone plus pen-
toxiphylline therapy was low with 9 dB. The relative
hearing was 49%. Including also only SSNHL of ≥30 dB
and using carbogen inhalation and prednisone orally,
Cvorovic et al. recently reported for 541 patients a
15.1 dB absolute hearing gain and a relative hearing gain
of 47%, i.e. in the range of the present study [5]. Using a
comparable treatment regime in one study arm, a recent
prospective trial reported an equivalent relative hearing
gain of 43% [9]. A spontaneous hearing recovery rate
without treatment for SSNHL of more than 25 dB and a
relative hearing gain of 47-63% is reported [10-12]. We
hypothesize that a negative selection bias is responsible
for high initial hearing loss and the relative less pro-
nounced hearing gain in the present study. First, only
patients with sudden hearing loss of ≥30 dB were in-
cluded. Second, inpatient treatment is mainly intended
(and only covered by health insurance) in Germany if
outpatient treatment fails to improve hearing within the
first days after onset of SSNHL or if other symptoms like
vertigo or severe hearing impairment on the contralat-
eral side are existent. In the present study sample half of
the patients had unsuccessful outpatient treatment be-
fore admission for inpatient treatment.
The two clinical factors: start of inpatient treatment
<4 days after onset and first SSNHL were associated with
better outcome. Furthermore, two audiological factors: low-
frequency hearing loss and initial hearing loss ≥60 dB were
related to better outcome. These results are partly in ac-
cordance to previous studies. It has been shown that hear-
ing recovery is greatest when corticosteroid treatment is
Table 4 Multivariate binary logistic regression analysis on independent prognostic factors for better outcome
measured as absolute hearing gain ≥ 10 dB
Parameter B S.E. Wald p Odds ratio 95% CI lower 95% CI upper
First SSNHL -1.280 0.445 8.291 0.004 3.597 1.506 8.621
Low-frequency type 1.238 0.692 3.205 0.073 3.450 0.889 13.389
Quick lower than reference value 0.388 0.669 0.337 0.562 1.474 0.397 5.469
Fibrinogen high (hyperfibrinogenemia) -0.967 0.451 4.595 0.032 2.631 1.086 6,369
Interval between onset and therapy begin <4 days 0.912 0.375 5.915 0.015 2.489 1.194 5.191
Initial hearing loss ≥60 dB -1.482 0.463 10.243 0.001 4.406 1.776 10.869
p values in bold are p values below 0.05, i.e. significant p values.
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[1,2,5,10]. Many studies revealed that low-frequency losses
do better than high-frequency losses [5,10,13,14]. More
severe initial hearing loss has higher probability of improve-
ment in some studies but in other studies a lower probabil-
ity [2,5,15]. In contrast to others, in present study vertigo
or impaired hearing on the contralateral ear had no nega-
tive prognostic influence [2,5,3]. The reason why vertigo
had no influence in the present study might be that patients
with acute vestibular deficits elicited by caloric testing were
strictly excluded.
If at all of interest, laboratory investigations were
mainly analyzed on their role as risk factors for SSNHL.
For instance, hypercholesterolemia and hyperglycemia
were observed more frequently in SSNHL patients than
in control populations [16,17]. Consistent to that, we
found a hypercholesterolemia in 38% and a hypergly-
cemia in 53% of the patients at the time of diagnosis
(cf. Table 1). Only a few studies have analyzed the prog-
nostic role of laboratory values on treatment outcome of
SSNHL. In two older studies, in times when CRP was
not yet part of routine blood examinations, an elevated
erythrocyte sedimentation rate was correlated to better
outcome [2,10]. In the present study CRP values had no
influence on outcome. As CRP is accepted to be more
sensitive and specific for acute inflammatory reactions
[18], and observing increased CRP values only for 7% of
the study sample, we state that acute inflammatory reac-
tion or an underlying inflammatory disease, respectively,
is not related to at least most cases of SSNHL and there-
fore does not play a prognostic role.
Univariate statistical analysis exposed that a decreased
Quick test value (<70%) at time of diagnosis was related
to better hearing gain. The Quick prothrombin time test
still is the basis for monitoring anticoagulant therapy in
many countries worldwide [19]. Unfortunately, Inter-
national normalized ratio (INR) values were not available
for the majority of patients. INR values would have the
advantage that the data would have been directly compar-
able to data from other laboratories. Seventeen (10%) of the
patients with SSNHL (initial hearing loss of these patients
was 65.4 ± 30.1 dB; 7 patients with initial loss ≥60 dB) hada decreased Quick value because of anticoagulant therapy
in accordance to anticoagulation guidelines for cardiac dis-
eases, history of stroke, peripheral arterial disease, or ven-
ous thromboembolism. Only patients under anticoagulant
therapy showed decreased Quick values. The anticoagulant
therapy was sustained during treatment of SSNHL holding
Quick values in the therapeutic range (data not shown).
The antithrombotic effects of the anticoagulants decrease
the viscosity of the plasma. We speculate that the combin-
ation of the SSNHL therapy with the anticoagulant
therapy significantly improved the microcirculatory
blood flow of the inner ear. In turn, this supports the
theory that a vascular impairment with disturbance of
the inner ear microcirculation is at least in some pa-
tients with SSNHL a causative factor [20,21].
Even more striking was the prognostic effect of fibrinogen
at time of diagnosis on the hearing gain as this parameter
remained also significantly relevant in the multivariate ana-
lysis. A quarter of patients had elevated fibrinogen values at
time of SSNHL diagnosis. It has been widely accepted that
hyperfibrinogenemia is an independent risk factor for car-
diovascular diseases [2]. Fibrinogen is the substrate for
thrombin and represents the final step in the coagulation
cascade and is essential for platelet aggregation [22]. Fur-
thermore, hyperfibrinogenemia seems to be a risk factor for
SSNHL [23,24]. This was the basis to introduce fibrinogen
apheresis as treatment option for SSNHL [9]. Recently,
it has been shown in guinea pigs that acute hyperfibri-
nogenemia has a direct negative impact on the cochlear
microcirculation [25]. We hypothesize that patients with
hyperfibrinogenemia in the present study sample had a
better outcome because a vascular factor/event trig-
gered the SSNHL. The treatment regime used primarily
was designed to improve the rheological blood performance
with the aim to improve the cochlear microcirculation [26].
If fibrinogen is qualified to be a biomarker for treat-
ment selection has to be proven by further prospective
trials. In deployment of the assumption that SSNHL is
an umbrella term for a disease with several causative
factors, such biomarkers are needed at least to select
patients with vascular origin of SSNHL as only these pa-
tients can profit optimally from vascular therapy regimes.
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The presented cohort study on 173 patients with SSNHL
revealed that beside clinical and audiological factors also
the laboratory markers: decreased Quick test value and a
hyperfibrinogenemia were positive prognostic markers for
better outcome using a treatment regime mainly intend-
ing to improve the cochlear microcirculation. Therefore,
hyperfibrinogenemia is not only a risk factor for SSNHL
but also a positive prognostic marker of outcome when
using a rheological regime to treat SSNHL. Especially
fibrinogen seems to be an interesting candidate as bio-
marker for better patient selection for treatment regi-
mens of SSNHL focusing on the refinement of cochlear
microcirculation.
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